AFINITOR for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 27 adverse event reports in the FDA FAERS database where AFINITOR was used for Renal cell carcinoma.
Most Reported Side Effects for AFINITOR
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 192 | 27.1% | 192 | 22 |
| Malignant neoplasm progression | 70 | 9.9% | 47 | 25 |
| Dyspnoea | 58 | 8.2% | 19 | 28 |
| Stomatitis | 57 | 8.1% | 17 | 17 |
| Diarrhoea | 47 | 6.6% | 11 | 27 |
| Fatigue | 44 | 6.2% | 9 | 16 |
| Cough | 34 | 4.8% | 8 | 16 |
| Pyrexia | 34 | 4.8% | 10 | 29 |
| Rash | 29 | 4.1% | 7 | 10 |
| Nausea | 28 | 4.0% | 7 | 15 |
| Drug ineffective | 27 | 3.8% | 5 | 5 |
| Anaemia | 26 | 3.7% | 11 | 14 |
| General physical health deterioration | 26 | 3.7% | 17 | 14 |
| Pneumonitis | 26 | 3.7% | 9 | 10 |
| Asthenia | 25 | 3.5% | 13 | 19 |
Other Indications for AFINITOR
Breast cancer (153)
Breast cancer metastatic (85)
Pancreatic neuroendocrine tumour (41)
Renal cancer (35)
Metastatic renal cell carcinoma (27)
Off label use (26)
Neuroendocrine tumour (24)
Angiomyolipoma (17)
Neoplasm malignant (13)
Breast cancer female (11)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
LENVATINIB (3,849)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
TIVOZANIB (1,258)